Dr. Ip on the Challenges of Treating Patients With Hematologic Malignancies and COVID-19

Video

Andrew Ip, MD, MS, discusses the challenges of treating patients with hematologic malignancies and COVID-19.

Andrew Ip, MD, MS, a hematologist/oncologist, John Theurer Cancer Center, Hackensack Meridian Health, discusses the challenges of treating patients with hematologic malignancies and COVID-19.

Treating COVID-19 has been difficult; however, unique challenges have emerged with regard to patients with lymphoma, leukemia, and myeloma, says Ip. Currently, approved agents to treat patients with COVID-19 include antiviral drugs, such as remdesivir (Veklury) alone or in combination with baricitinib (Olumiant). Dexamethasone has also demonstrated activity in managing inflammation related to COVID-19. Convalescent plasma, an immune-based therapy that can provide passive immunity, has also been granted Emergency Use Authorization to treat patients with COVID-19. Finally, tocilizumab (Actemra), a monoclonal antibody that is used to treat patients with hematologic malignancies who develop cytokine storm from cellular therapies, has also demonstrated efficacy in treating patients with COVID-19.

Despite these advances, treating patients with hematologic malignancies who develop COVID-19 is challenging because many are on immunosuppressive medications, such as rituximab (Rituxan), CD20-directed monoclonal antibodies or chemotherapy, says Ip. Additionally, patients with cancer and COVID-19 can have severe and prolonged COVID-19 symptoms, Ip explains. As such, additional research is needed to determine the utility of these therapies among patients with hematologic malignancies, concludes Ip.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD